Idiopathic pulmonary fibrosis (IPF) is a chronic disease for which novel approaches are
urgently required. We reported increased sphingosine kinase 1 (SPHK1) in IPF lungs and …

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disease,
wherein transforming growth factor β (TGF-β) and sphingosine-1-phosphate (S1P) …

Transforming growth factor β (TGF-β) contributes to the progression of pulmonary fibrosis
through up-regulation of α–smooth muscle actin (α–SMA) as lung myofibroblast …

Abstract Sphingosine 1-phosphate (S1P) levels are often found to be elevated in serum,
bronchoalveolar lavage, and lung tissue of idiopathic pulmonary fibrosis patients and …

Idiopathic pulmonary fibrosis is an agnogenic chronic disorder with high morbidity and low
survival rate. Quercetin is a flavonoid found in a variety of herbs with anti-fibrosis function. In …

Background Idiopathic pulmonary fibrosis (IPF) is characterised by the aberrant epithelial to
mesenchymal transition (EMT) and myofibroblast accumulation. Sphingosine-1-phosphate …

Idiopathic pulmonary fibrosis (IPF) is a devastating disease characterized by alveolar
epithelial cell injury, accumulation of fibroblasts/myofibroblasts and deposition of …

Idiopathic pulmonary fibrosis is a devastating disease with poor prognosis. The pathogenic
role of the lysophospholipid mediator sphingosine-1-phosphate and its receptor S1PR2 in …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease which leads to
significant morbidity and mortality from respiratory failure. The two drugs currently approved …

Idiopathic pulmonary fibrosis is a progressive fibrotic disorder with no cure that is
characterized by deterioration of lung function. Current FDA-approved drugs for IPF delay …